Delivery Order HHSN261201200035I-HHSN26100008
- This is a federal contract award from the National Cancer Institute (NCI), a civilian agency within the Department of Health and Human Services (HHS), to Northwestern University. The contract is titled "CANCER PREVENTION AGENT DEVELOPMENT PROGRAM: EARLY PHASE CLINICAL RESEARCH" and is a delivery order under the "Cancer Prevention Agent Development Program 2012-2017" indefinite delivery vehicle (IDV). The contract has a ceiling value of $2,031,555.74 and a period of...
- This is a federal contract award from the National Cancer Institute (NCI) to Northwestern University, a private research university, for a Phase I clinical trial to evaluate the dermal tolerability and safety of an endoxifen gel in women undergoing breast surgery. The contract, which is part of NCI's Cancer Prevention Agent Development Program, has a ceiling value of $481,539.10 and a period of performance through August 31, 2023. Northwestern University is the prime contractor, with...
- This federal contract award, with a ceiling value of $826,870.34, was issued by the National Cancer Institute (NCI) to Northwestern University for a Phase I clinical trial of inhaled iloprost to prevent lung cancer in former smokers. The award is part of the NCI's Cancer Prevention Agent Development Program, which supports early-phase research to evaluate novel cancer prevention agents. Northwestern University, a private research university, is serving as the prime contractor for this work....
- This federal contract award was issued by the Department of Health and Human Services' National Institutes of Health National Heart Lung and Blood Institute to Northwestern University, a private research university located in Evanston, Illinois. The contract, titled "CARDIA CHICAGO FC DIVERSITY SUPPLEMENT - TASK AREA E", has a potential value of $252,786.45 and is a Delivery Order contract with a Cost No Fee pricing type. The contract does not have a set-aside designation. The award...
- This is a federal contract award from the National Cancer Institute, part of the Department of Health and Human Services, to Northwestern University, a private research university, for a Cancer Prevention Agent Development Program project. The contract has a ceiling value of $946,472.83 and a period of performance ending August 31, 2023. The objective is to conduct a randomized, double-blind, placebo-controlled Phase II clinical trial examining the effects of simvastatin versus placebo on...
- This is a $8,557,717.62 definitive contract awarded by the National Institute of Child Health and Human Development (NICHD), a component of the U.S. Department of Health and Human Services, to Northwestern University for "The National Standard for Normal Fetal Growth" research. The contract has an ultimate completion date of August 25, 2015 and is a cost-no-fee arrangement. Northwestern University, a private research university located in Evanston, Illinois, is the prime contractor...
- This federal contract award, with a ceiling value of $1,159,347.10, was issued by the National Cancer Institute (NCI) to Northwestern University. The contract is part of the NCI's "Cancer Prevention Agent Development Program: Early Phase Clinical Research" and involves a Phase IIB clinical trial to evaluate the efficacy of topical 4-hydroxytamoxifen versus oral tamoxifen in treating ductal carcinoma in situ (DCIS) of the breast. Northwestern University is the prime contractor, and...
- The National Cancer Institute awarded Northwestern University a $250,000 firm fixed-price purchase order on November 1, 2024, for medical record abstraction services supporting the Pediatric Proton and Photon Therapy Comparison Cohort study. Under this 20-month contract extending through June 30, 2026, Northwestern University will retrieve and abstract de-identified clinical and treatment data from medical records of pediatric cancer patients treated with proton or photon radiotherapy. The...
- This is a federal contract award from the Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases to Northwestern University. The award is a 5-year definitive contract with a potential value of $25,631,560.21 to support the "Structural Genomics Centers for Infectious Diseases" program. This contract does not have a set-aside designation. As the prime contractor, Northwestern University will provide research,...
- This federal contract award was made by the National Cancer Institute, a civilian agency within the U.S. Department of Health and Human Services, to Northwestern University, a private research university. The $96,000.31 award supports a Phase I clinical trial of the compound berberine in subjects with ulcerative colitis, as part of the agency's Cancer Prevention Agent Development Program. The contract has no set-aside designation. The prime contractor, Northwestern University, will oversee the...
- HHSN261201200035IIndefinite Delivery Contract
- HHSN261201200035I-HHSN26100008Delivery Order
This is a federal contract award from the National Cancer Institute (NCI), a component of the Department of Health and Human Services (HHS), to Northwestern University. The $3,544,085.97 contract is part of the Cancer Prevention Agent Development Program and provides core infrastructure support for early-phase clinical research. The contract is a delivery order under a larger IDV (Indefinite Delivery Vehicle) contract titled "Cancer Prevention Agent Development Program 2012-2017". Northwestern University, a private research university, is serving as the prime contractor on this award. The contract has no set-aside designation and the performance location is in Chicago, Illinois. This award demonstrates Northwestern University's expertise in supporting federal agencies like the NCI through provision of consulting services, technical assistance, and research and development to advance cancer prevention efforts.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| P00007 | Funding Only Action | ($450k) | 3/3/22 | |
| P00006 | Funding Only Action | ($4k) | 4/8/21 | |
| P00005 | Funding Only Action | ($40k) | 2/12/20 | |
| 4 | Exercise an Option | $1.2m | 7/25/18 | |
| 3 | Exercise an Option | $1.2m | 9/12/17 |